Labcorp to Launch Alzheimer's Blood Test in Primary-Care Settings
By Rob Curran
Labcorp Holdings said it would soon offer a blood test for diagnosing Alzheimer's disease in primary-care settings.
The Burlington, N.C., lab-services company on Thursday said the Elecsys pTau181 test, developed by Swiss drugmaker Roche Holding and approved for commercialization by the U.S. Food and Drug Administration, would be available nationwide in early 2026. It will be the first such test available to primary-care providers in the U.S.
The test measures phosphorylated Tau 181 protein in human plasma, a key biomarker for Alzheimer's, said Labcorp. In trials, the test was found to rule out Alzheimer's pathology with a 97.9% negative predictive value, Labcorp said, citing Roche.
In August, Labcorp launched an Alzheimer's diagnostic test developed by Fujirebio Diagnostics intended for use in specialized-care settings.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
October 23, 2025 09:31 ET (13:31 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States